EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Veracyte's Enterprise Value is $1,438.5 Mil.
Veracyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-70.4 Mil. Therefore, Veracyte's EV-to-EBIT for today is -20.43.
The historical rank and industry rank for Veracyte's EV-to-EBIT or its related term are showing as below:
VCYT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -173.75 Med: -18.67 Max: -2.93
Current: -20.43
During the past 13 years, the highest EV-to-EBIT of Veracyte was -2.93. The lowest was -173.75. And the median was -18.67.
VCYT's EV-to-EBIT is ranked worse than 100% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 21.93
vs VCYT: -20.43
The historical data trend for Veracyte's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Veracyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veracyte's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Veracyte's EV-to-EBIT falls into.
Veracyte's current Enterprise Value is $1,438.5 Mil.
Veracyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte (NAS:VCYT) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Veracyte's Enterprise Value for the quarter that ended in Mar. 2024 was $1,498.4 Mil.
Veracyte's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veracyte EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Veracyte's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCYT has been successfully added to your 